On Sept. 24 it announced plans to begin human trials. Its stock was up close to 2 percent at closing. GlaxoSmithKline’s stock rose on the news as well. The pharmaceutical giant came to its Ebola research through the acquisition of a small …
We maintain our Sell rating on GlaxoSmithKline Pharma (GSK) and revise our TP to Rs1,525 (earlier Rs1,390) based on 24x March’19E EPS of Rs63.4. GSK’s Q2FY18 results exceeded our and consensus estimates. GSK revenue grew by …
One stock that might be an intriguing choice for investors right now is GlaxoSmithKline plc GSK. This is because this security in the Large Cap Pharmaceuticals space is seeing solid earnings estimate revision activity, and is in great …
GSK's dividend is arguably the greatest lure of owning this stock, so a cut would be concerning. I'd have to admit that buying Pfizer's consumer-health division would be a bit perplexing considering that GSK completed a major …
For 2018, EPS guidance was given, as last year, bearing in mind the uncertainty over the timing and impact of possible generic competition to GSK's Advair asthma drug in the US. In the event of no substitutable generic competitor, …
So far GlaxoSmithKline plc (ADR) (NYSE:GSK)’s stock price appears to be unaffected by the news, and there is not much concern that the investigation will seriously harm the company’s profits. Even if this is the beginning of a difficult …
Century Aluminum (NASDAQ:CENX): JP Morgan moves the stock to Underweight from Neutral. GlaxoSmithKline (NYSE:GSK): Pharmaceutical giant GlaxoSmithKline sees its stock downgraded to Hold from Buy at Deutsche …
However following its stock market surge, chief executive Gavin Patterson cannot afford any slips. Verdict: Avoid. Inside the City then moves on to GlaxoSmithKline, which had a turbulent 2014. However investors think it may be about to turn …